Furthermore, the cell growth inhibition by gefitinib correlated with HAb18G/CD147 levels: cell growth decreased 1.96-3.95 fold in cells with HAb18G/CD147 knock-down and increased 1.62-fold in cells with HAb18G/CD147 knock-in (Figure 4E), indicating that EGFR acts downstream of HAb18G/CD147 in pancreatic cancer cells. Here, BSG is linked to familial pancreatic carcinoma.